Study of Immune Tolerance and Capacity for Wound Healing of Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Completed

• Conditions: Recessive Dystrophic Epidermolysis Bullosa
• Interventions: Other: Blood collection; Other: Skin biopsies

• Registration Number: NCT01874769
• Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Brief Summary

Recessive Dystrophic Epidermolysis Bullosa (RDEB) is one of the most severe rare inherited skin disorders affecting children and adults. Current medical care protocols for RDEB patients are limited to palliative procedures to treat blistering and erosive lesions, wounds, and severe local and systemic complications such as fusion and contracture of the digits, skin cancer, esophageal stricture, severe anemia, infections, malnutrition and growth retardation. However, current medical treatments still cannot prevent the recurrence of the lesions arising from defective expression of type VII collagen (COL7A1), the main constituent of anchoring fibrils which form essential structures for dermal-epidermal adherence.

The purpose of this study is to investigate the capacity of keratinocytes and fibroblasts to repair skin wounds in patients suffering from Recessive Dystrophic Epidermolysis Bullosa (RDEB).

Detailed Description

In the perspective of future therapeutic interventions, which could involve protein, cellular and/or gene therapy, it is essential to investigate RDEB patients with regards to their immune tolerance to type VII collagen and their capacity of their cells for tissue reconstruction.

Study Timeline

• Study First Submitted: 2013-04-03
• Study First Submitted QC: 2013-06-07
• Study First Posted: 2013-06-11
• Study Start: 2013-08
• Primary Completion: 2017-08
• Study Completion: 2017-08
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-27
• Last Update Posted: 2025-01-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Confirmed molecular diagnosis of recessive dystrophic epidermolysis bullosa, established for both alleles;
• Non severe generalized clinical form of RDEB;
• Presence of type VII collagen on skin biopsy and/or western-blot analysis detected with a set of specific antibodies;
• Presence of intact skin areas without blisters, infection or erosion;
• Absence of hospitalization related to EB condition;
• Patients and their parents when applicable should be able and willing to return for follow up;
• Patients should be able and willing to give signed informed consent. For patients who are minor, informed consent will be signed by a legally authorized representative, as well as an assent form by the minor patient.
• Ability to undergo local anesthesia.

Exclusion Criteria

• Severity of disease and presence of ill-prognostic features:

  1. Premature termination codon in the noncollagenous (NC1) domain of COL7A1 on both alleles;
  2. Absence of detectable type VII collagen expression on skin biopsy and Western blot analysis from cultured cells;

• Underlying conditions, diseases or active infections likely to increase the risk of complications or to interfere with the biological investigations:

  1. History of current or previous skin cancer (Squamous cell carcinoma or other malignant skin cancer);
  2. Current infectious diseases, including systemic infections and known positive HIV serology (Kaposi's sarcoma), hepatitis B and C;
  3. History of current psychological or psychiatric disease;
  4. Absence of an adequate familial and social support;
  5. History of current or previous organ diabetes mellitus;
  6. Non corrected severe anemia (Hemoglobin level: < 8 g/ml);
  7. Non corrected iron deficiency;
  8. History of significant allergy to an anaesthetic procedure
  9. Patient currently receiving anticoagulant or anti-aggregation treatment;
  10. Participation in another clinical trial or therapy protocol for RDEB at the time of study inclusion
  11. Positive pregnancy urinary test or lactating women

• Not affiliated to the national social security/health service beneficiary and families with beneficiary children.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Blood collection and skin biopsies	Skin biopsies	-
Blood collection and skin biopsies	Blood collection	-

Primary Outcome Measures

Name	Time	Method
Determination of the proliferative capacity of keratinocytes and fibroblasts in characterized RDEB patients	Month 23	Populations of keratinocytes and fibroblasts isolated from punch biopsies will be analyzed for their proliferative capacity.

Secondary Outcome Measures

Name	Time	Method
Clinical evaluation and scoring	Month 9	Clinical evaluation and scoring will be assessed using The Birmingham Epidermolysis Bullosa Severity score.
Assessment of type VII collagen expression and anchoring fibrils formation in the skin	Month 9	Punch biopsies of the patient skin will be taken and processed for cell culture (keratinocytes and fibroblasts) and for histological and ultrastructural analyses.
Identification of COL7A1 mutations	Month 9	COL7A1 mutations will be screened by direct sequencing of peripheral blood DNA using a set of primers designed to sequence the 118 COL7A1 exons and their intronic junctions.

Trial Locations

Locations (3)

Service de dermatologie Necker Hospital for sick children; 🇫🇷 Paris, France

Inserm U781 Service de Génétique Necker Hospital for sick children; 🇫🇷 Paris, France

Guy's and ST Thomas NHS Foundation trust/Guy's Hospital; 🇬🇧 London, United Kingdom